Perindopril: a Review of Its Use in Patients with or at Risk of Developing Coronary Artery Disease

Overview

Journal Drugs

Specialty Pharmacology

Date 2006 Feb 3

PMID 16451098

Citations 3

Authors

Monique P Curran

Paul L McCormack

Dene Simpson

Affiliations

Soon will be listed here.

Abstract

Perindopril (Coversyl) is a prodrug ester of perindoprilat, an ACE inhibitor. This agent has shown pharmacodynamic effects beyond those responsible for lowering blood pressure (BP), including the improvement of endothelial function and the normalisation of vascular and cardiac structure and function. Perindopril has a well established role in the treatment of patients with hypertension or heart failure. In the EUROPA trial, once-daily perindopril 8 mg prevented cardiovascular events in patients with stable coronary artery disease (CAD) without any apparent heart failure receiving standard recommended therapy. In the ASCOT-BPLA trial, a calcium channel antagonist +/- perindopril regimen demonstrated significant cardiovascular benefits compared with a conventional beta-blocker +/- diuretic regimen in patients with hypertension who were at risk of developing cardiovascular events. These trials demonstrate that while perindopril, in addition to standard recommended therapy, has a potential role in preventing cardiovascular events in hypertensive patients, its role in the management of patients with stable CAD is clearly established.

Citing Articles

Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use.

Syed Y Am J Cardiovasc Drugs. 2022; 22(2):219-230.

PMID: 35257306 PMC: 8964631. DOI: 10.1007/s40256-022-00521-0.

Efficient access to enantiomerically pure cyclic alpha-amino esters through a lipase-catalyzed kinetic resolution.

Alatorre-Santamaria S, Rodriguez-Mata M, Gotor-Fernandez V, de Mattos M, Sayago F, Jimenez A Tetrahedron Asymmetry. 2010; 19(14):1714-1719.

PMID: 20104250 PMC: 2587339. DOI: 10.1016/j.tetasy.2008.06.010.

Perindopril versus angiotensin II receptor blockade in hypertension and coronary artery disease: implications of clinical trials.

Brady A Clin Drug Investig. 2007; 27(3):149-61.

PMID: 17305412 DOI: 10.2165/00044011-200727030-00001.

References

Fennessy P, Campbell J, Mendelsohn F, Campbell G . Angiotensin-converting enzyme inhibitors and atherosclerosis: relevance of animal models to human disease. Clin Exp Pharmacol Physiol. 1996; 23(8):S30-2. DOI: 10.1111/j.1440-1681.1996.tb03038.x. View

Poulter N, Wedel H, Dahlof B, Sever P, Beevers D, Caulfield M . Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet. 2005; 366(9489):907-13. DOI: 10.1016/S0140-6736(05)67186-3. View

St John Sutton M, Pfeffer M, Plappert T, Rouleau J, Moye L, Dagenais G . Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril. Circulation. 1994; 89(1):68-75. DOI: 10.1161/01.cir.89.1.68. View

Asmar R, Topouchian J, Pannier B, Benetos A, Safar M . Pulse wave velocity as endpoint in large-scale intervention trial. The Complior study. Scientific, Quality Control, Coordination and Investigation Committees of the Complior Study. J Hypertens. 2001; 19(4):813-8. DOI: 10.1097/00004872-200104000-00019. View

Ambrosioni E, Borghi C, Magnani B . The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N Engl J Med. 1995; 332(2):80-5. DOI: 10.1056/NEJM199501123320203. View

Speirs C, Wagniart F, Poggi L . Perindopril postmarketing surveillance: a 12 month study in 47,351 hypertensive patients. Br J Clin Pharmacol. 1998; 46(1):63-70. PMC: 1873977. DOI: 10.1046/j.1365-2125.1998.00031.x. View

Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G . Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342(3):145-53. DOI: 10.1056/NEJM200001203420301. View

Hurst M, Jarvis B . Perindopril: an updated review of its use in hypertension. Drugs. 2001; 61(6):867-96. DOI: 10.2165/00003495-200161060-00020. View

Navookarasu N, Rahman A, Abdullah I . First-dose response to angiotensin-converting enzyme inhibition in congestive cardiac failure: a Malaysian experience. Int J Clin Pract. 1999; 53(1):25-30. View

10.

Kool M, Lustermans F, Breed J, Struyker Boudier H, Hoeks A, Reneman R . The influence of perindopril and the diuretic combination amiloride+hydrochlorothiazide on the vessel wall properties of large arteries in hypertensive patients. J Hypertens. 1995; 13(8):839-48. DOI: 10.1097/00004872-199508000-00004. View

11.

London G, Pannier B, Guerin A, Marchais S, Safar M, Cuche J . Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. Circulation. 1994; 90(6):2786-96. DOI: 10.1161/01.cir.90.6.2786. View

12.

Zhuo J, Froomes P, Casley D, Liu J, Murone C, Chai S . Perindopril chronically inhibits angiotensin-converting enzyme in both the endothelium and adventitia of the internal mammary artery in patients with ischemic heart disease. Circulation. 1997; 96(1):174-82. View

13.

Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo Jr J . Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003; 42(6):1206-52. DOI: 10.1161/01.HYP.0000107251.49515.c2. View

14.

Schwartzkopff B, Brehm M, Mundhenke M, Strauer B . Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension. 2000; 36(2):220-5. DOI: 10.1161/01.hyp.36.2.220. View

15.

Bertrand M, Remme W, Fox K, Ferrari R, Simoons M . Effects of perindopril on long-term clinical outcome of patients with coronary artery disease and preserved left ventricular function. Int J Cardiol. 2007; 121(1):57-61. DOI: 10.1016/j.ijcard.2006.11.100. View

16.

Grandi A, Venco A, Barzizza F, Petrucci E, Scalise F, Perani G . Double-blind comparison of perindopril and captopril in hypertension. Effects on left ventricular morphology and function. Am J Hypertens. 1991; 4(6):516-20. DOI: 10.1093/ajh/4.6.516. View

17.

Antman E, Anbe D, Armstrong P, Bates E, Green L, Hand M . ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise.... Circulation. 2004; 110(5):588-636. DOI: 10.1161/01.CIR.0000134791.68010.FA. View

18.

Julius S, Kjeldsen S, Weber M, Brunner H, Ekman S, Hansson L . Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363(9426):2022-31. DOI: 10.1016/S0140-6736(04)16451-9. View

19.

Ghiadoni L, Magagna A, Versari D, Kardasz I, Huang Y, Taddei S . Different effect of antihypertensive drugs on conduit artery endothelial function. Hypertension. 2003; 41(6):1281-6. DOI: 10.1161/01.HYP.0000070956.57418.22. View

20.

Vitovec J, Spinar J . First-dose hypotension after angiotensin-converting enzyme (ACE) inhibitors in chronic heart failure: a comparison of enalapril and perindopril. Slovak Investigator Group. Eur J Heart Fail. 2000; 2(3):299-304. DOI: 10.1016/s1388-9842(00)00095-7. View